1. Home
  2. Companies
  3. VFY
  4. Material Events

Vitrafy Life Sciences (ASX:VFY) — Material Events

ASX:VFY · 16 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 15 articles Notable 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
15
Vitrafy Advances Cryopreservation Tech with 75% Sales Growth and FY26 Commercial LaunchesMedium
Vitrafy reports strong FY25 growth, advances cryopreservation tech, targets FY26 commercial launches
5 Aug 2025 ·Financial Results Presentation ·85
Vitrafy Raises A$30 Million to Scale US Cryopreservation OperationsMedium
Vitrafy Life Sciences raises A$30 million via institutional placement to fund US growth and manufacturing
12 June 2026 ·Capital Raising ·85
Vitrafy Partners with Vitalant to Fill Red Blood Cell Cryopreservation VoidMedium
Vitrafy partners with Vitalant to address red blood cell cryopreservation technology gap
2 June 2026 ·Partnership Announcement ·Unexpected ·85
Vitrafy and IMV Forge Exclusive Deal to Revolutionise Animal CryopreservationMedium
Vitrafy and IMV Technologies form exclusive 12-month partnership to commercialize advanced animal cryopreservation technology
15 Jan 2026 ·Strategic Partnership Announcement ·85
Vitrafy Advances Cryopreservation Tech Amid $32.7M FY25 Loss and $35M IPOMedium
Vitrafy reports $32.7M loss in FY25, advances cryopreservation tech post $35M IPO and $4.8M grant
5 Aug 2025 ·Annual Report ·85
Vitrafy Secures IMV Deal, Launches Guardion in North America, Advances US Military TestingHigh
Vitrafy secures IMV deal, launches Guardion in North America, advances US military testing, and reports $22.8m cash
29 Jan 2026 ·Quarterly Activities Report & Appendix 4C ·85
Vitrafy’s No-Wash Platelet Cryopreservation Clears US Army Phase II HurdleMedium
Vitrafy completes successful US Army Phase II platelet cryopreservation study with superior no-wash protocol
22 May 2026 ·Clinical Study Results ·85
Vitrafy Advances No-Wash Platelet Tech and Eyes FDA Milestone Amid Supply DelaysMedium
Vitrafy completes Phase II military platelet study with strong results, advances FDA registration and commercial partnerships
28 Apr 2026 ·Quarterly Activities Report & Appendix 4C ·80
Vitrafy and U.S. Army Complete Phase II Platelet Cryopreservation Study with Promising No-Wash Protocol ResultsMedium
Vitrafy and U.S. Army Complete Phase II Platelet Cryopreservation Study with Promising No-Wash Protocol Results
8 Apr 2026 ·ASX Announcement ·80
Vitrafy Advances Commercialisation with IMV Deal and U.S. Expansion in 1H FY26Medium
Vitrafy delivers 1H FY26 milestones, secures IMV deal, advances clinical studies, maintains strong cash runway
4 Feb 2026 ·Financial Results Presentation ·80
Vitrafy Unveils First VCU2 Unit, Accelerates US Expansion and CommercialisationMedium
Vitrafy delivers first VCU2 unit, advances US expansion and commercialisation, maintains strong cash position
22 Oct 2025 ·Quarterly Activities Report & Appendix 4C ·80
Vitrafy Advances Cryopreservation Tech, Eyes FY26 Launch with Strong Cash BackingMedium
Vitrafy advances cryopreservation tech and commercial pipeline, targets FY26 product launch with strong cash position
30 July 2025 ·Quarterly Activities Report & Appendix 4C ·75
Vitrafy Charts Clear Path to Commercialisation with FY25 Gains and FY26 LaunchesMedium
Vitrafy FY25 results show strong sales growth, technology progress, and clear FY26 commercialisation path
5 Aug 2025 ·Financial Results Presentation ·75
Vitrafy Secures Strategic Deal with IMV, Unlocking Animal Market AccessMedium
Vitrafy inks 12-month strategic partnership with IMV in animal reproduction, securing up to A$930k in fees
15 Jan 2026 ·Strategic Partnership Announcement ·75
Vitrafy Names Co-Founder Brent Owens as New CEO Amid Leadership ShiftMedium
Vitrafy appoints Brent Owens as new CEO, Kate Munnings to retire and remain on board
5 Aug 2025 ·Board and Executive Change ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.